Olmesartan in Essential Hypertension | NCT00185172 | Trialant

Olmesartan in Essential Hypertension | NCT00185172 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
1	Placebo Comparator	2 week placebo run-in	Other: placebo
2	Experimental	Olmesartan medoxomil tablets for 8 weeks	Drug: olmesartan medoxomil
3	Experimental	Olmesartan medoxomil tablets, or olmesartan medoxomil tablets + hydrochlorothiazide tablets for 4 weeks	Drug: olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
To compare the efficacy on diastolic blood pressure of 40 mg olmesartan to a combination of 20 mg olmesartan and 12.5 mg hydrochlorothiazide in patients who are not sufficiently responding to treatment with 20 mg olmesartan.		From week 8 to week 12

Secondary Outcomes

Measure	Description	Time Frame
To assess the effects on systolic and diastolic blood pressure of 20 mg olmesartan, 40 mg olmesartan and the combination of 20 mg olmesartan with 12.5 mg hydrochlorothiazide at week 2, 4, 8 and 12.		12 weeks
To detect less frequent adverse drug reactions and assess the safety and tolerability of olmesartan.

Contacts/Locations Module

Condition Browse Module

Intervention Browse Module